Boston Scientific Downgraded as PFA, Watchman Stall; Forecasts 7% Growth, $3.65 EPS
BSX•An analyst cut Boston Scientific to Peer Perform after pulsed field ablation and Watchman device growth stalled sharply in H1 2026. The revised model forecasts 7% organic revenue growth in 2027, $3.65 in earnings per share and a low-$50s price target.
1. Analyst Rating Cut
A leading sell-side analyst downgraded Boston Scientific to Peer Perform, marking the end of its multiyear bullish thesis as growth catalysts faltered.
2. PFA and Watchman Setbacks
Pulsed field ablation growth is pressured by intensified Abbott pricing and bundling competition, while Watchman device adoption faces implanter fee cuts and catheter lab capacity constraints.
3. Revised Projections
Forecasts now assume just 7% organic revenue growth in 2027, $3.65 earnings per share and imply a share price in the low $50s.
4. Capital Allocation Concerns
The analyst criticized recent acquisitions, notably Axonics, as execution risks that further weigh on the company’s growth outlook.
